These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32815739)

  • 1. The SELUTION SLR™ drug-eluting balloon system for the treatment of symptomatic femoropopliteal lesions.
    Böhme T; Noory E; Beschorner U; Macharzina R; Zeller T
    Future Cardiol; 2021 Mar; 17(2):257-267. PubMed ID: 32815739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-Month Outcomes From the First-in-Human, Single-Arm SELUTION Sustained-Limus-Release Drug-Eluting Balloon Trial in Femoropopliteal Lesions.
    Zeller T; Brechtel K; Meyer DR; Noory E; Beschorner U; Albrecht T
    J Endovasc Ther; 2020 Oct; 27(5):683-690. PubMed ID: 32666871
    [No Abstract]   [Full Text] [Related]  

  • 3. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
    Caradu C; Lakhlifi E; Colacchio EC; Midy D; Bérard X; Poirier M; Ducasse E
    J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
    Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intervention with selution SLR™ Agent Balloon for Endovascular Latent Limus therapy for failing AV Fistulas (ISABELLA) Trial: Protocol for a pilot clinical study and pre-clinical results.
    Tang TY; Chong TT; Yap CJQ; Soon SXY; Chan SL; Tan RY; Yap HY; Tay HT; Tan CS; Barnhill S; Hellinga D; DeGraw RT; Finn AV
    J Vasc Access; 2023 Mar; 24(2):289-299. PubMed ID: 34219511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
    J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
    Mehrotra S; Paramasivam G; Mishra S
    Curr Cardiol Rep; 2017 Feb; 19(2):10. PubMed ID: 28185166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease.
    Bausback Y; Wittig T; Schmidt A; Zeller T; Bosiers M; Peeters P; Brucks S; Lottes AE; Scheinert D; Steiner S
    J Am Coll Cardiol; 2019 Feb; 73(6):667-679. PubMed ID: 30765033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World's First Experience Treating TASC II C and D Tibial Occlusive Disease Using the Selution SLR Sirolimus-Eluting Balloon: Six-Month Results From the PRESTIGE Study.
    Tang TY; Yap C; Soon SXY; Chan SL; Lee QS; Yap HY; Tay HTL; Chong TT
    J Endovasc Ther; 2021 Aug; 28(4):555-566. PubMed ID: 33843364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries.
    Mohapatra A; Saadeddin Z; Bertges DJ; Madigan MC; Al-Khoury GE; Makaroun MS; Eslami MH
    J Vasc Surg; 2020 Feb; 71(2):560-566. PubMed ID: 31405761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
    Phair J; Carnevale M; Lipsitz EC; Shariff S; Scher L; Garg K
    Ann Vasc Surg; 2020 Jul; 66():595-600. PubMed ID: 31863948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
    Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
    Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 12-Months Results From the PRESTIGE Study Using Sirolimus Drug-Eluting Balloons in the Treatment of Complex BTK Tibial Atherosclerotic Lesions in CLTI Patients.
    Tang TY; Yap CJQ; Soon SXY; Chan SL; Khoo VBX; Chong TT
    Cardiovasc Revasc Med; 2022 Oct; 43():143-146. PubMed ID: 35414445
    [No Abstract]   [Full Text] [Related]  

  • 14. Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease.
    Herten M; Torsello GB; Schönefeld E; Stahlhoff S
    Vasc Health Risk Manag; 2016; 12():341-56. PubMed ID: 27621646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality Not Correlated With Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon.
    Schneider PA; Laird JR; Doros G; Gao Q; Ansel G; Brodmann M; Micari A; Shishehbor MH; Tepe G; Zeller T
    J Am Coll Cardiol; 2019 May; 73(20):2550-2563. PubMed ID: 30690141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
    Bausback Y; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    J Endovasc Ther; 2017 Aug; 24(4):459-467. PubMed ID: 28558502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison of sirolimus- versus paclitaxel-coated balloon angioplasty in the femoropopliteal artery: study protocol for the randomized controlled SIRONA trial.
    Teichgräber U; Ingwersen M; Platzer S; Lehmann T; Zeller T; Aschenbach R; Scheinert D
    Trials; 2021 Sep; 22(1):665. PubMed ID: 34583746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions.
    Steiner S; Schmidt A; Zeller T; Tepe G; Thieme M; Maiwald L; Schröder H; Euringer W; Ulrich M; Brechtel K; Brucks S; Blessing E; Schuster J; Langhoff R; Schellong S; Weiss N; Scheinert D
    Eur Heart J; 2020 Jul; 41(27):2541-2552. PubMed ID: 31989155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK.
    Katsanos K; Geisler BP; Garner AM; Zayed H; Cleveland T; Pietzsch JB
    BMJ Open; 2016 May; 6(5):e011245. PubMed ID: 27160845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
    Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
    Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.